Biological E acquires Akorn injectable plant in India
BE is in the process of developing a COVID-19 vaccine and may be able to use the facilities at Akorn India Paonta Sahib Plant in Himachal pradesh for commercial scale manufacture of the vaccine at the appropriate time, it said.;
Hyderabad : Biological E. Limited (BE), a city-based pharmaceuticals and biologics company on Monday announced the acquisition of Akorn India Limited, a subsidiary of Akorn Inc, USA, for an undisclosed sum.
By this strategic acquisition, BE will be able to enhance its manufacturing capabilities and capacities to produce and supply its vaccines and injectable medicines, a press release from the company said.
BE is in the process of developing a COVID-19 vaccine and may be able to use the facilities at Akorn India Paonta Sahib Plant in Himachal Pradesh for commercial scale manufacture of the vaccine at the appropriate time, it said.
The Akorn India plant has a fully staffed sterile injectable manufacturing facility with a 39,000 sq.mtrs of built-up area spread over a 14-acre campus with an annual capacity for about 135 Million Units with the potential for immediate expansion of a further 30 Million Units, it said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.